Skip to content
Colorectal Cancer Clinical Trials

Aurora, Colorado

Colorectal cancer clinical trials in Aurora, CO

43 colorectal cancer studies are recruiting participants at sites in Aurora as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Aurora at a glance

  • 43 studies are recruiting at a site in Aurora.
  • By phase: Phase 1 (10), Phase 1/2 (11), Phase 2 (2), Phase 2/3 (1), Phase 3 (6), No phase (6), Observational (7). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (27), university, hospital or other (14), government (2).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Aurora

Basic details from each study's public record (the 30 most recently updated of 43). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    UCHealth University of Colorado Hospital
    Registry record
    NCT05863195 · updated
  2. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study site
    University of Colorado
    Registry record
    NCT06983743 · updated
  3. A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07213609 · updated
  4. Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCHealth University of Colorado Hospital
    Registry record
    NCT06102902 · updated
  5. A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    University of Colorado Cancer Center
    Registry record
    NCT04929223 · updated
  6. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  7. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Rocky Mountain Regional VA Medical Center · UCHealth University of Colorado Hospital
    Registry record
    NCT05080673 · updated
  8. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    UCHealth University of Colorado Hospital
    Registry record
    NCT05174169 · updated
  9. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Rocky Mountain Regional VA Medical Center · UCHealth University of Colorado Hospital
    Registry record
    NCT05334069 · updated
  10. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study site
    Rocky Mountain Cancer Centers-Aurora
    Registry record
    NCT06418204 · updated
  11. A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Colorado Denver Anschultz Medical Campus
    Registry record
    NCT06663319 · updated
  12. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    University of Colorado Denver Anschultz Medical Campus
    Registry record
    NCT06750094 · updated
  13. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    University of Colorado Hospital
    Registry record
    NCT07584226 · updated
  14. LYL273 for Patients With Relapsed or Refractory mCRC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    University of Colorado Hospital - Anschutz Cancer Pavilion
    Registry record
    NCT05319314 · updated
  15. A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Sarah Cannon Research Institute Scri Oncology Partners
    Registry record
    NCT07284849 · updated
  16. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    University of Colorado Anschutz Medical Campus ( Site 0299) · University of Colorado Anschutz Medical Campus ( Site 0325) · University of Colorado Anschutz Medical Campus ( Site 0326)
    Registry record
    NCT06428409 · updated
  17. A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT06885034 · updated
  18. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Rocky Mountain Cancer Centers - Aurora /ID# 280112
    Registry record
    NCT07525206 · updated
  19. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Rocky Mountain Cancer Centers, LLP
    Registry record
    NCT07222800 · updated
  20. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    University of Colorado
    Registry record
    NCT05919264 · updated
  21. Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

    • No phase
    • Ages 65 to 82
    • All sexes
    Sponsor
    Dartmouth-Hitchcock Medical Center
    Study site
    University of Colorado
    Registry record
    NCT05612347 · updated
  22. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    University of Colorado Cancer Center
    Registry record
    NCT06128551 · updated
  23. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    University of Colorado Hospital-Anschutz Cancer Pavilion
    Registry record
    NCT06445062 · updated
  24. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    University of Colorado
    Registry record
    NCT05059444 · updated
  25. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    University of Colorado Cancer Center
    Registry record
    NCT06253871 · updated
  26. Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCHealth University of Colorado Hospital
    Registry record
    NCT07147231 · updated
  27. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    University of Colorado Hospital
    Registry record
    NCT03715933 · updated
  28. Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

    • Phase 2
    • Ages 18 to 100
    • All sexes
    Sponsor
    University of Colorado, Denver
    Study site
    University of Colorado Cancer Center
    Registry record
    NCT07292298 · updated
  29. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Children's Hospital Colorado
    Registry record
    NCT04851119 · updated
  30. Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

    • Observational
    • Ages 18 to 99
    • All sexes
    Sponsor
    University of Colorado, Denver
    Study site
    University of Colorado Denver
    Registry record
    NCT05517811 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Aurora, CO on ClinicalTrials.gov.

Ask about studies near Aurora

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Colorado

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call